Lupin’s shares jumps nearly 2% to intra-day high of Rs 2156 on NSE after the Indian generic drugmaker reported a stronger-than-expected rise in second-quarter profit, driven by strong demand for its respiratory and diabetes management drugs.
Profit and Revenue Growth
The company posted a remarkable 74.1% year-on-year surge in its consolidated net profit for the July-September quarter of FY25, which stood at Rs 852.63 crore, up from Rs 489.67 crore in the same period last year. This profit growth was primarily fueled by higher sales across various markets.
Also ReadLupin Share Price Today Live Updates, 08 Nov, 2024: Lupin on the radar
Revenue for the quarter came in at Rs 5,672.73 crore, reflecting a 12.6% increase from Rs 5,038.56 crore in the corresponding quarter of FY24.
Also Read Premier Energies rises 8% as subsidiaries bag multiple orders worth Rs 560 crore ABB India shares drop over 5% on cautious outlook for new order wins in FY25 Bajaj Auto shares plunge over 5% as October sales miss estimates Sun Pharma shares slip over 3% after US court’s ruling on LEQSELVI launch
Strong Performance in Key Markets
In the North American market, Lupin’s Q2 sales reached Rs 1,971.1 crore, a 5.6% increase from Rs 1,866.6 crore last year, contributing to 36% of the company’s global sales.
Also ReadMarkets slide, give up Trump-fuelled gains
In India, the company’s formulation sales stood at Rs 2,009.6 crore, marking an 18.8% rise from Rs 1,691.5 crore in the same period last year, accounting for 37% of its global sales.
EBITDA and Margin Improvement
Lupin’s earnings before interest, taxes, depreciation, and amortization (EBITDA) surged 44.3% to Rs 1,382.7 crore, up from Rs 958.2 crore in the year-ago period. The company’s EBITDA margin expanded significantly, reaching 25.2%, compared to 19.4% in the same quarter last year.
Stock Performance in Last One Year
Lupin shares have delivered positive returns across various time frames. Over the last three months, the stock has shown a positive return of 3%, indicating short-term growth. In the last six months, the performance has been even more impressive, with a substantial increase of 30.65%, showcasing the stock’s resilience and upward momentum.
Year-to-date, Lupin shares have surged by 59.61%, emphasizing the stock’s positive trajectory in the current calendar year.
» Read More
